The Korean journal of internal medicine

  • 제31권2호
  • /
  • Pages.219-236
  • /
  • 2016
  • /
  • 1226-3303(pISSN)
  • /
  • 2005-6648(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

The specialist physician's approach to rheumatoid arthritis in South Africa

  • Bester, Frederik C.J. (Department of Internal Medicine, Rosepark Life Health Care Hospital) ;
  • Bosch, Fredricka J. (Department of Internal Medicine, Rosepark Life Health Care Hospital) ;
  • Jansen van Rensburg, Barend J. (Department of Internal Medicine, University of Free State Medical School)
  • 투고 : 2015.05.08
  • 심사 : 2015.05.08
  • 발행 : 2016.03.01
⟨ 이전 논문 다음 논문 ⟩

초록

Rheumatoid arthritis (RA) is expected to increase in Africa and South Africa. Due to the low numbers of rheumatologists in South Africa, specialist physicians also have to care for patients with RA. Furthermore several new developments have taken place in recent years which improved the management and outcome of RA. Classification criteria were updated, assessment follow-up tools were refined and above all, several new biological disease-modifying anti-rheumatic drugs were developed. Therefore it is imperative for specialist physicians to update themselves with the newest developments in the management of RA. This article provides an overview of the newest developments in the management of RA in the South African context. This approach may well apply to countries with similar specialist to patient ratios and disease profiles.

키워드

참고문헌

  1. Still L. Health Care in South Africa. Johannesburg: Profile Media, 2014.
  2. Fellingham SA, Elphinstone CD, Wittmann W. Mseleni joint disease: background and prevalence. S Afr Med J 1973;47:2173-2180.
  3. Tikly M. The scourge of HIV infection in sub-Saharan Africa: a rheumatological perspective. J Rheumatol 2011;38:973-974. https://doi.org/10.3899/jrheum.110119
  4. Asherson RA. The catastrophic antiphospholipid syndrome. J Rheumatol 1992;19:508-512.
  5. McGill P. Rheumatoid arthritis in sub-Saharan Africa. Ann Rheum Dis 1991;50:965-966. https://doi.org/10.1136/ard.50.12.965
  6. Mody GM, Meyers OL. Rheumatoid arthritis in blacks in South Africa. Ann Rheum Dis 1989;48:69-72. https://doi.org/10.1136/ard.48.1.69
  7. Okada H, Kuhn C, Feillet H, Bach JF. The 'hygiene hypothesis' for autoimmune and allergic diseases: an up-date. Clin Exp Immunol 2010;160:1-9.
  8. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324. https://doi.org/10.1002/art.1780310302
  9. Singh JA, Furst DE, Bharat A, et al. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625-639. https://doi.org/10.1002/acr.21641
  10. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-2581. https://doi.org/10.1002/art.27584
  11. Hodkinson B, Van Duuren E, Pettipher C, Kalla A; South African Rheumatism and Arthritis Association. South African recommendations for the management of rheumatoid arthritis: an algorithm for the standard of care in 2013. S Afr Med J 2013;103(8 Pt 2):576-585. https://doi.org/10.7196/SAMJ.7047
  12. Wolfe F. 50 Years of antirheumatic therapy: the prognosis of rheumatoid arthritis. J Rheumatol Suppl 1990;22:24-32.
  13. Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000;43:22-29. https://doi.org/10.1002/1529-0131(200001)43:1<22::AID-ANR4>3.0.CO;2-9
  14. Hulsmans HM, Jacobs JW, van der Heijde DM, van Albada-Kuipers GA, Schenk Y, Bijlsma JW. The course of radiologic damage during the first six years of rheumatoid arthritis. Arthritis Rheum 2000;43:1927-1940. https://doi.org/10.1002/1529-0131(200009)43:9<1927::AID-ANR3>3.0.CO;2-B
  15. O'Dell JR. How is it best to treat early rheumatoid arthritis patients? Best Pract Res Clin Rheumatol 2001;15:125-137. https://doi.org/10.1053/berh.2000.0130
  16. Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004;43:906-914. https://doi.org/10.1093/rheumatology/keh199
  17. Arthritis Care. Have you got the S factor? 2013 [Internet]. London (UK): Arthritis Care, c2015 [cited 2015 Oct 25]. Available from: http://www.arthritiscare.org.uk/AboutArthritis/HaveyougottheSfactor.
  18. Beattie KA, MacIntyre NJ, Cividino A. Screening for signs and symptoms of rheumatoid arthritis by family physicians and nurse practitioners using the gait, arms, legs, and spine musculoskeletal examination. Arthritis Care Res (Hoboken) 2012;64:1923-1927. https://doi.org/10.1002/acr.21740
  19. Wiesinger T, Smolen JS, Aletaha D, Stamm T. Compression test (Gaenslen's squeeze test) positivity, joint tenderness, and disease activity in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2013;65:653-657. https://doi.org/10.1002/acr.21863
  20. van der Heijde DM, van't Hof MA, van Riel PL, Van de Putte L. Disease activity score. Ann Rheum Dis 1992;51:140.
  21. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005;23(5 Suppl 39):S100-S108.
  22. Aletaha D, Nell VP, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7:R796-R806. https://doi.org/10.1186/ar1740
  23. Smolen JS, Aletaha D. The assessment of disease activity in rheumatoid arthritis. Clin Exp Rheumatol 2010;28(3 Suppl 59):S18-S27.
  24. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology: preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-735. https://doi.org/10.1002/art.1780380602
  25. Knevel R, Schoels M, Huizinga TW, et al. Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69:987-994. https://doi.org/10.1136/ard.2009.126748
  26. Kirwan JR, Reeback JS. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol 1986;25:206-209. https://doi.org/10.1093/rheumatology/25.2.206
  27. Hazes JM. Determinants of physical function in rheumatoid arthritis: association with the disease process. Rheumatology (Oxford) 2003;42 Suppl 2:ii17-ii21.
  28. Scott DL, Smith C, Kingsley G. Joint damage and disability in rheumatoid arthritis: an updated systematic review. Clin Exp Rheumatol 2003;21(5 Suppl 31):S20-S27.
  29. Gossec L, Dougados M, Goupille P, et al. Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. Ann Rheum Dis 2004;63:675-680. https://doi.org/10.1136/ard.2003.010611
  30. Wakefield RJ, Kong KO, Conaghan PG, Brown AK, O'Connor PJ, Emery P. The role of ultrasonography and magnetic resonance imaging in early rheumatoid arthritis. Clin Exp Rheumatol 2003;21(5 Suppl 31):S42-S49.
  31. Hammer HB, Haavardsholm EA. Advances in imaging. Curr Opin Rheumatol 2012;24:299-305. https://doi.org/10.1097/BOR.0b013e3283521c90
  32. Yazici Y, Erkan D, Paget SA. Monitoring methotrexate hepatic toxicity in rheumatoid arthritis: is it time to update the guidelines? J Rheumatol 2002;29:1586-1589.
  33. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009;68:1100-1104. https://doi.org/10.1136/ard.2008.093690
  34. Kalla AA, Stanwix A, Gotlieb D, Asherson RA, Mody GM. Rheumatoid arthritis: clinical guideline 2003. S Afr Med J 2003;93(12 Pt 2):991-1012.
  35. Kirwan JR, Bijlsma JW, Boers M, Shea BJ. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 2007;(1):CD006356.
  36. Mouterde G, Dernis E, Ruyssen-Witrand A, et al. Indications of glucocorticoids in early arthritis and rheumatoid arthritis: recommendations for clinical practice based on data from the literature and expert opinion. Joint Bone Spine 2010;77:597-603. https://doi.org/10.1016/j.jbspin.2009.12.011
  37. Gorter SL, Bijlsma JW, Cutolo M, et al. Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69:1010-1014. https://doi.org/10.1136/ard.2009.127332
  38. Horton S, Buch MH, Emery P. Efficacy, tolerability and safety of biologic therapy in rheumatoid disease: patient considerations. Drug Healthc Patient Saf 2010;2:101-119.
  39. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-975. https://doi.org/10.1136/ard.2009.126532
  40. Hodkinson B, Musenge E, Ally M, Meyer PW, Anderson R, Tikly M. Response to traditional disease-modifying anti-rheumatic drugs in indigent South Africans with early rheumatoid arthritis. Clin Rheumatol 2012;31:613-619. https://doi.org/10.1007/s10067-011-1900-5
  41. Khanna D, Oh M, Furst DE, et al. Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort. Arthritis Rheum 2007;57:440-447. https://doi.org/10.1002/art.22619
  42. Isaacs JD, Ferraccioli G. The need for personalised medicine for rheumatoid arthritis. Ann Rheum Dis 2011;70:4-7. https://doi.org/10.1136/ard.2010.135376
  43. Reynolds A, Koenig AS, Bananis E, Singh A. When is switching warranted among biologic therapies in rheumatoid arthritis? Expert Rev Pharmacoecon Outcomes Res 2012;12:319-333. https://doi.org/10.1586/erp.12.27
  44. Chan FK, Abraham NS, Scheiman JM, Laine L; First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Am J Gastroenterol 2008;103:2908-2918. https://doi.org/10.1111/j.1572-0241.2008.02200.x
  45. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006;296:1633-1644. https://doi.org/10.1001/jama.296.13.jrv60011
  46. Hill J. Rheumatology nurse specialists: do we need them? Rheumatology (Oxford) 2007;46:379-381. https://doi.org/10.1093/rheumatology/kel431
  47. Baka Z, Buzas E, Nagy G. Rheumatoid arthritis and smoking: putting the pieces together. Arthritis Res Ther 2009;11:238. https://doi.org/10.1186/ar2751
  48. Skytta ET, Honkanen PB, Eskelinen A, Huhtala H, Remes V. Fewer and older patients with rheumatoid arthritis need total knee replacement. Scand J Rheumatol 2012;41:345-349. https://doi.org/10.3109/03009742.2012.681061
  49. Baronnet L, Barnetche T, Kahn V, Lacoin C, Richez C, Schaeverbeke T. Incidence of tuberculosis in patients with rheumatoid arthritis: a systematic literature review. Joint Bone Spine 2011;78:279-284. https://doi.org/10.1016/j.jbspin.2010.12.004
  50. Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003;3:148-155. https://doi.org/10.1016/S1473-3099(03)00545-0
  51. Winthrop KL, Siegel JN, Jereb J, Taylor Z, Iademarco MF. Tuberculosis associated with therapy against tumor necrosis factor alpha. Arthritis Rheum 2005;52:2968-2974. https://doi.org/10.1002/art.21382
  52. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005;52:1766-1772. https://doi.org/10.1002/art.21043
  53. Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010;69:522-528. https://doi.org/10.1136/ard.2009.118935
  54. Jasmer RM, Nahid P, Hopewell PC. Clinical practice: latent tuberculosis infection. N Engl J Med 2002;347:1860-1866. https://doi.org/10.1056/NEJMcp021045
  55. Menzies R, Vissandjee B. Effect of bacille Calmette-Guerin vaccination on tuberculin reactivity. Am Rev Respir Dis 1992;145:621-625. https://doi.org/10.1164/ajrccm/145.3.621
  56. Pouchot J, Grasland A, Collet C, Coste J, Esdaile JM, Vinceneux P. Reliability of tuberculin skin test measurement. Ann Intern Med 1997;126:210-214. https://doi.org/10.7326/0003-4819-126-3-199702010-00005
  57. Dheda K, Udwadia ZF, Huggett JF, Johnson MA, Rook GA. Utility of the antigen-specific interferon-gamma assay for the management of tuberculosis. Curr Opin Pulm Med 2005;11:195-202. https://doi.org/10.1097/01.mcp.0000158726.13159.5e
  58. Pooran A, Booth H, Miller RF, et al. Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis. BMC Pulm Med 2010;10:7. https://doi.org/10.1186/1471-2466-10-7
  59. Denkinger CM, Dheda K, Pai M. Guidelines on interferon-$\gamma$ release assays for tuberculosis infection: concordance, discordance or confusion? Clin Microbiol Infect 2011;17:806-814. https://doi.org/10.1111/j.1469-0691.2011.03555.x
  60. Martinson NA, Barnes GL, Moulton LH, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med 2011;365:11-20. https://doi.org/10.1056/NEJMoa1005136
  61. World Health Organization. South African tuberculosis profile 2011 [Internet]. Pretoria (ZA): Health, c2015 [cited 2015 Oct 25]. Available from: http://www.who.int/tb/data.
  62. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000;161(4 Pt 2):S221-S247. https://doi.org/10.1164/ajrccm.161.supplement_3.ats600
  63. Tam LS, Leung CC, Ying SK, et al. Risk of tuberculosis in patients with rheumatoid arthritis in Hong Kong: the role of TNF blockers in an area of high tuberculosis burden. Clin Exp Rheumatol 2010;28:679-685.
  64. Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009;60:1884-1894. https://doi.org/10.1002/art.24632
  65. Wallis RS. Biologics and infections: lessons from tumor necrosis factor blocking agents. Infect Dis Clin North Am 2011;25:895-910. https://doi.org/10.1016/j.idc.2011.08.002
  66. Nam JL, Winthrop KL, van Vollenhoven RF, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010;69:976-986. https://doi.org/10.1136/ard.2009.126573
  67. Handa R, Misra R, Chaturvedi VP, et al. Guidelines for tuberculosis prophylaxis during anti-tumour necrosis factor-$\alpha$ treatment: Indian Rheumatology Association. APLAR J Rheumatol 2006;9:181-183. https://doi.org/10.1111/j.1479-8077.2006.00181.x
  68. El Maghraoui A, Benbouzza K, Bezza A, et al. Recommandations de la Societe Marocaine de Rhumatologie pour la prise en charge de la polyarthrite rhumatoide. Rev Maroc Rhumatol 2007;2-3:45-61.
  69. Xanthouli P, Sailer S, Fiehn C. Rituximab (RTX) as an alternative to TNF-alpha antagonists in patients with rheumatoid arthritis and high risk of severe infections: a systematic analysis of the experience in one center. Open Rheumatol J 2012;6:286-289. https://doi.org/10.2174/1874312901206010286
  70. Rehle TM, Hallett TB, Shisana O, et al. A decline in new HIV infections in South Africa: estimating HIV incidence from three national HIV surveys in 2002, 2005 and 2008. PLoS One 2010;5:e11094. https://doi.org/10.1371/journal.pone.0011094
  71. Mody GM, Parke FA, Reveille JD. Articular manifestations of human immunodeficiency virus infection. Best Pract Res Clin Rheumatol 2003;17:265-287. https://doi.org/10.1016/S1521-6942(03)00003-2
  72. McLean-Tooke A, Aldridge C, Waugh S, Spickett GP, Kay L. Methotrexate, rheumatoid arthritis and infection risk: what is the evidence? Rheumatology (Oxford) 2009;48:867-871. https://doi.org/10.1093/rheumatology/kep101
  73. Paton NI, Aboulhab J. Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks. HIV Med 2005;6:13-20. https://doi.org/10.1111/j.1468-1293.2005.00259.x
  74. Ndakotsu MA, Salawu L, Durosinmi MA. Relation between erythrocyte sedimentation rate, clinical and immune status in HIV-infected patients. Niger J Med 2009;18:208-210.
  75. Vigano M, Degasperi E, Aghemo A, Lampertico P, Colombo M. Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. Expert Opin Biol Ther 2012;12:193-207. https://doi.org/10.1517/14712598.2012.646986
  76. Ferri C, Govoni M, Calabrese L. The A, B, Cs of viral hepatitis in the biologic era. Curr Opin Rheumatol 2010;22:443-450. https://doi.org/10.1097/BOR.0b013e328338f6df
  77. Peters MJ, van Halm VP, Voskuyl AE, et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum 2009;61:1571-1579. https://doi.org/10.1002/art.24836
  78. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69:325-331. https://doi.org/10.1136/ard.2009.113696
  79. Klug E; South African Heart Association (S A Heart); Lipid and Atherosclerosis Society of Southern Africa (LASSA). South African dyslipidaemia guideline consensus statement. S Afr Med J 2012;102(3 Pt 2):178-187. https://doi.org/10.7196/SAMJ.5502
  80. Gabriel SE, Crowson CS. Risk factors for cardiovascular disease in rheumatoid arthritis. Curr Opin Rheumatol 2012;24:171-176. https://doi.org/10.1097/BOR.0b013e32834ff2fd
  81. Westlake SL, Colebatch AN, Baird J, et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2010;49:295-307. https://doi.org/10.1093/rheumatology/kep366
  82. Vis M, Havaardsholm EA, Haugeberg G, et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:1495-1499. https://doi.org/10.1136/ard.2005.044198
  83. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002;13:777-787. https://doi.org/10.1007/s001980200108
  84. Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010;62:1515-1526. https://doi.org/10.1002/acr.20295
  85. Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54:692-701. https://doi.org/10.1002/art.21675
  86. Askling J, van Vollenhoven RF, Granath F, et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Arthritis Rheum 2009;60:3180-3189. https://doi.org/10.1002/art.24941
  87. Buch MH, Smolen JS, Betteridge N, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:909-920. https://doi.org/10.1136/ard.2010.144998
  88. Raaschou P, Simard JF, Neovius M, Askling J; Anti-Rheumatic Therapy in Sweden Study Group. Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents. Arthritis Rheum 2011;63:1812-1822. https://doi.org/10.1002/art.30247
  89. Boulman N, Rimar D, Rozenbaum M, Slobodin G, Younis S, Rosner I. Anti-tumor necrosis factor treatment and pregnancy: the way is open. Clin Exp Rheumatol 2012;30:453.
  90. Visser K, Katchamart W, Loza E, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009;68:1086-1093. https://doi.org/10.1136/ard.2008.094474
  91. Roy S. Number needed to treat for biologic therapies in patients with active rheumatoid arthritis despite methotrexate: a mixed treatment comparison meta-analysis. Ann Rheum Dis 2011;70(Suppl 3):432.

피인용 문헌

  1. Commentary: Systemic Lupus Erythematosus in Native sub-Saharan Africans: A Systematic Review and Meta-Analysis vol.7, pp.None, 2016, https://doi.org/10.3389/fmed.2020.00202